ASND vs GMAB

Ascendis Pharma A/S and Genmab A/S, both Healthcare

Ascendis Pharma A/S is the larger company at $17B against $16B. Over the past year GMAB returned +31% against +16% for ASND. The RyuScore puts GMAB ahead, 84 against 9 out of 100.

Ascendis Pharma A/S and Genmab A/S compared on valuation, return and the RyuScore
FigureASNDGMAB
Last close$229$37.06
Market cap$17B$16B
1-year return+16%+31%
5-year return+49%-15%
RyuScoresector-relative, 1–109/10084/100

Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.

Ascendis Pharma A/S

Revenue of $248M in Q4 2025, net income null.

ASND overviewrevenue and segmentsvaluation

Genmab A/S

Revenue of $12B in H2 2024, net income $5.1B.

GMAB overviewrevenue and segmentsvaluation

Open these two in the interactive comparison to add more names, change the period or see the correlation.